ClinicalTrials.gg
Active, not recruitingNCT03690388Updated Oct 20, 2026Results posted

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

A Phase 3 interventional study of Cabozantinib and Placebo in Differentiated Thyroid Cancer, sponsored by Exelixis. Active, not recruiting at 164 sites in 25 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Exelixis · Phase 3, Interventional, and Treatment

Updated Oct 20, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
187
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in Thyroid Cancer, Papillary with a site in United States — 9 open to participants now, 19 under way, 1 of them phase 3. Thyroid Cancer, Papillary · United States.

Enrollment
4th of 62
187 · median 25
Started
2018
with 2 others
Phase 3
2 of 75
none open now
Primary completion
2020-08
later than 0 of 17 live
Registered
52nd of 75
by date
Lead sponsor
3 of 75
Exelixis

Among the 75 studies in Thyroid Cancer, Papillary with a site in United States, this one is the 4th largest by enrollment of the 62 interventional ones that give a count, is one of 3 that started in 2018, is one of 2 in phase 3, reaches primary completion later than 0 of the 17 other live ones, and was the 52nd registered.

Thyroid Cancer, Papillary

186 studies on the registry are indexed under Thyroid Cancer, Papillary; 51 are open to participants now.

Browse Thyroid Cancer, Papillary studies →

Open to participants now

9 of the 75 studies in Thyroid Cancer, Papillary with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Thyroid Cancer, Papillary studies recruiting now, 20 (61%) set no upper age limit and 8 (24%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Thyroid Cancer, Papillary with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior vascular endothelial growth factor receptor (VEGFR)-Targeted therapy.

03

Conditions studied

  • Differentiated Thyroid Cancer

Keywords

  • Thyroid cancer, papillary
  • Papillary thyroid carcinoma
  • Nonmedullary thyroid carcinoma
  • Cancer of the thyroid
  • Thyroid cancer
  • Follicular thyroid cancer
  • Thyroid cancer, follicular
  • Hürthle cell cancer
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed diagnosis of Differentiated Thyroid Cancer (DTC)
  2. according to (RECIST) 1.1
  3. Previously treated with or deemed ineligible for treatment with Iodine- 131 for differentiated thyroid cancer (DTC)
  4. Previously treated with at least one of the following vascular endothelial growth factor receptor (VEGFR)-targeting tyrosine kinase inhibitor (TKI) agents for DTC: lenvatinib or sorafenib. Note: Up to two prior VEGFR-targeting TKI agents are allowed
  5. (ECOG) performance status (PS) of 0 or 1

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with any of the following: Cabozantinib; Selective small-molecule v-raf murine sarcoma viral oncogene homolog B1 (BRAF) kinase inhibitor; More than 2 VEGFR-targeting TKI agents; More than 1 therapy; 1 systemic chemotherapy regimen (given as single agent or in combination with another chemotherapy agent)
  2. Receipt of any type of small molecule kinase inhibitor (including kinase inhibitor) within 2 weeks or 5 half-lives of the agent, whichever is longer, before randomization
  3. Receipt of any type of anticancer antibody (including investigational antibody) or systemic chemotherapy within 4 weeks before randomization
  4. Receipt of radiation therapy for bone within 2 weeks or any other radiation therapy within 4 weeks before randomization.
  5. Known or cranial epidural disease unless adequately treated
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
187 participants (actual)

Study arms

  • Experimental
    Cabozantinib

    cabozantinib (60 mg) once daily orally (qd)

    Drug: Cabozantinib

  • Placebo comparator
    Placebo

    placebo once daily orally (qd)

    Drug: Placebo

Interventions

  • Tablets containing 60-mg or 20-mg cabozantinib once daily orally.

    Also known as: XL184, Cabometyx®

  • DrugPlacebo

    Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    Time to the earlier of either radiographic progressive disease (PD) or death from any cause.

    Time frame: Up to approximately twenty months after the first subject is randomized. Time from randomization to the earlier of the following events: radiographic PD as determined by the blinded independent central review (BIRC) or death due to any cause.

  2. Objective Response Rate (ORR)

    Proportion of subjects with the best overall response of complete response (CR) or partial response (PR).

    Time frame: Six months after 100 subjects are randomized. Time from randomization to best overall response of confirmed complete response (CR) or confirmed partial response (PR) per BIRC per RECIST 1.1.

07

Results

Posted May 18, 2023

Participant flow

Participant flow — Overall Study
MilestoneCabozantinibPlacebo
Started12562
Completed8926
Not completed3636
Withdrew: Adverse event81
Withdrew: Radiographic progression1429
Withdrew: Clinical deterioration106
Withdrew: Withdrawal by subject20
Withdrew: Lack of efficacy10
Withdrew: Lost to follow-up10

Outcome measures

PrimaryProgression Free Survival (PFS)

Time to the earlier of either radiographic progressive disease (PD) or death from any cause.

Time frame:
Up to approximately twenty months after the first subject is randomized. Time from randomization to the earlier of the following events: radiographic PD as determined by the blinded independent central review (BIRC) or death due to any cause.
Reported as:
Median · months
Progression Free Survival (PFS)
monthsCabozantinibPlacebo
Progression Free Survival (PFS)NA (5.7 to NA)1.9 (1.8 to 3.6)
Statistical analysis
  • Cabozantinib vs Placebo · Log Rank · p = < 0.0001 · Hazard ratio (hr): 0.22 · 96% CI 0.13 to 0.36
PrimaryObjective Response Rate (ORR)

Proportion of subjects with the best overall response of complete response (CR) or partial response (PR).

Time frame:
Six months after 100 subjects are randomized. Time from randomization to best overall response of confirmed complete response (CR) or confirmed partial response (PR) per BIRC per RECIST 1.1.
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsCabozantinibPlacebo
Objective Response Rate (ORR)15 (5.8 to 29.3)0 (0.0 to 14.8)

Adverse events

Collected over 1 year, 8 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cabozantinib17/125 (13.6%)43/125 (34.4%)112/125 (89.6%)
Placebo14/62 (22.6%)18/62 (29%)32/62 (51.6%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventCabozantinibPlacebo
DyspnoeaRespiratory, thoracic and mediastinal disorders4/1254/62
Pleural effusionRespiratory, thoracic and mediastinal disorders4/1253/62
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/1250/62
DiarrhoeaGastrointestinal disorders4/1250/62
Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/1250/62
HydrothoraxRespiratory, thoracic and mediastinal disorders0/1251/62
PainGeneral disorders1/1251/62
Oedema peripheralGeneral disorders1/1251/62
Pain in jawMusculoskeletal and connective tissue disorders0/1251/62
PneumoniaInfections and infestations2/1251/62
Most frequent other events
Showing 10 of 38
Most frequent other events
EventCabozantinibPlacebo
DiarrhoeaGastrointestinal disorders69/1252/62
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders59/1250/62
FatigueGeneral disorders41/1255/62
HypertensionVascular disorders37/1253/62
NauseaGastrointestinal disorders33/1251/62
Decreased appetiteMetabolism and nutrition disorders33/12510/62
Alanine aminotransferase increasedInvestigations32/1251/62
Aspartate aminotransferase increasedInvestigations32/1251/62
HypocalcaemiaMetabolism and nutrition disorders30/1251/62
Weight decreasedInvestigations25/1253/62

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CabozantinibPlaceboTotal
<=18 years000
Between 18 and 65 years622991
>=65 years633396
Age, Continuous
Age, Continuous(years)CabozantinibPlaceboTotal
Median65 (32 to 85)66 (37 to 81)66 (32 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)CabozantinibPlaceboTotal
Female6834102
Male572885
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CabozantinibPlaceboTotal
Hispanic or Latino21627
Not Hispanic or Latino9553148
Unknown or Not Reported9312
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CabozantinibPlaceboTotal
American Indian or Alaska Native303
Asian201434
Native Hawaiian or Other Pacific Islander000
Black or African American123
White9041131
More than one race000
Unknown or Not Reported11516
Region of Enrollment
Region of Enrollment(participants)CabozantinibPlaceboTotal
Hong Kong011
United States10919
Czechia101
Thailand213
Russia8311
Austria404
Netherlands112
South Korea8816
Brazil11415
Poland9413
France8311
Croatia101
Argentina101
Romania314
Hungary538
United Kingdom437
Spain10919
Canada303
Belgium325
Taiwan639
Italy14519
Mexico303
Israel303
Australia516
Germany213
Receipt of prior lenvatinib
Receipt of prior lenvatinib(Participants)CabozantinibPlaceboTotal
Count of participants7939118
08

Study locations

164 sites
  • Exelixis Clinical Site #2
    Newport Beach, California 92658, United States
  • Exelixis Clinical Site #98
    Sacramento, California 95817, United States
  • Exelixis Clinical Site #69
    San Francisco, California 94115, United States
  • Exelixis Clinical Site #10
    Stanford, California 94305, United States
  • Exelixis Clinical Site #3
    Torrance, California 90502, United States
  • Exelixis Clinical Site #9
    Aurora, Colorado 80045, United States
  • Exelixis Clinical Site #21
    New Haven, Connecticut 06510, United States
  • Exelixis Clinical Site #4
    Washington D.C., District of Columbia 20010, United States
  • Exelixis Clinical Site #94
    Miami, Florida 33136, United States
  • Exelixis Clinical Site #93
    Orlando, Florida 32804, United States
  • Exelixis Clinical Site #6
    Tampa, Florida 33612, United States
  • Exelixis Clinical Site #164
    Chicago, Illinois 60637, United States
  • Exelixis Clinical Site #54
    Lexington, Kentucky 40536, United States
  • Exelixis Clinical Site #153
    Boston, Massachusetts 02114, United States
  • Exelixis Clinical Site #80
    Ann Arbor, Michigan 48109, United States
  • Exelixis Clinical Site #78
    Detroit, Michigan 48201, United States
  • Exelixis Clinical Site #22
    Detroit, Michigan 48202, United States
  • Exelixis Clinical Site #63
    Columbia, Missouri 65212, United States
  • Exelixis Clinical Site #42
    St Louis, Missouri 63110, United States
  • Exelixis Clinical Site #11
    Omaha, Nebraska 68114, United States
  • Exelixis Clinical Site #118
    Morristown, New Jersey 07962, United States
  • Exelixis Clinical Site #76
    Charlotte, North Carolina 28204, United States
  • Exelixis Clinical Site #19
    Durham, North Carolina 27710, United States
  • Exelixis Clinical Site #7
    Cincinnati, Ohio 45219, United States
  • Exelixis Clinical Site #5
    Bethlehem, Pennsylvania 18015, United States
  • Exelixis Clinical Site #1
    Philadelphia, Pennsylvania 19104, United States
  • Exelixis Clinical Site #75
    Pittsburgh, Pennsylvania 15232, United States
  • Exelixis Clinical Site #134
    Charleston, South Carolina 29425, United States
  • Exelixis Clinical Site #68
    Nashville, Tennessee 37232, United States
  • Exelixis Clinical Site #8
    Houston, Texas 77030, United States
  • Exelixis Clinical Site #113
    Seattle, Washington 98109, United States
  • Exelixis Clinical Site #96
    Pergamino, Buenos Aires B2700CPM, Argentina
  • Exelixis Clinical Site #97
    Caba, C1012AAR, Argentina
  • Exelixis Clinical Site #129
    Córdoba, X5000AVE, Argentina
  • Exelixis Clinical Site #17
    St Leonards, New South Wales 2065, Australia
  • Exelixis Clinical Site #25
    Waratah, New South Wales 2298, Australia
  • Exelixis Clinical Site #86
    Bedford Park, South Australia 5042, Australia
  • Exelixis Clinical Site #24
    Melbourne, Victoria 3004, Australia
  • Exelixis Clinical Site #12
    Herston, 4029, Australia
  • Exelixis Clinical Site #62
    Salzburg, 5020, Austria
  • Exelixis Clinical Site #119
    Vienna, 1090, Austria
  • Exelixis Clinical Site #90
    Anderlecht, 1070, Belgium
  • Exelixis Clinical Site #31
    Brussels, 1200, Belgium
  • Exelixis Clinical Site #26
    Edegem, 2650, Belgium
  • Exelixis Clinical Site #74
    Edegem, 2650, Belgium
  • Exelixis Clinical Site #100
    Ghent, 9000, Belgium
  • Exelixis Clinical Site #27
    Namur, 5000, Belgium
  • Exelixis Clinical Site #35
    Cascavel, Paraná 85806-300, Brazil
  • Exelixis Clinical Site #39
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Exelixis Clinical Site #140
    Porto Alegre, Rio Grande do Sul 90050-170, Brazil
  • Exelixis Clinical Site #38
    Porto Alegre, Rio Grande do Sul 90110-270, Brazil
  • Exelixis Clinical Site #116
    Ribeirão Preto, São Paulo 14051-140, Brazil
  • Exelixis Clinical Site #40
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • Exelixis Clinical Site #92
    Rio de Janeiro, 20231-050, Brazil
  • Exelixis Clinical Site #47
    São Paulo, 01246-000, Brazil
  • Exelixis Clinical Site #20
    Calgary, Alberta T2N 4N2, Canada
  • Exelixis Clinical Site #18
    Edmonton, Alberta T6G 1Z2, Canada
  • Exelixis Clinical Site #107
    London, Ontario N6A 5W9, Canada
  • Exelixis Clinical Site #83
    Toronto, Ontario M5G 2M9, Canada
  • Exelixis Clinical Site #145
    Osijek, 31000, Croatia
  • Exelixis Clinical Site #137
    Zagreb, 10000, Croatia
  • Exelixis Clinical Site #138
    Zagreb, 10000, Croatia
  • Exelixis Clinical Site #105
    Brno, 656 53, Czechia
  • Exelixis Clinical Site #104
    Olomouc, 779 00, Czechia
  • Exelixis Clinical Site #32
    Dijon, Bourgogne-Franche-Comté 21079, France
  • Exelixis Clinical Site #67
    Bordeaux, New Aquitaine 33075, France
  • Exelixis Clinical Site #45
    Angers, Pays de la Loire Region 4933, France
  • Exelixis Clinical Site #72
    Marseille, Provence-Alpes-Côte d'Azur Region 13915, France
  • Exelixis Clinical Site #102
    Besançon, 25030, France
  • Exelixis Clinical Site #91
    Lyon, 69373, France
  • Exelixis Clinical Site #82
    Nice, 06189, France
  • Exelixis Clinical Site #152
    Paris, 75013, France
  • Exelixis Clinical Site #95
    Strasbourg, 67065, France
  • Exelixis Clinical Site #44
    Villejuif, Île-de-France Region 94805, France
  • Exelixis Clinical Site #121
    Tübingen, Baden-Wurttemberg 72076, Germany
  • Exelixis Clinical Site #156
    Würzburg, Bavaria 97080, Germany
  • Exelixis Clinical Site #125
    Marburg, Hesse 35043, Germany
  • Exelixis Clinical Site #163
    Hanover, Lower Saxony 30625, Germany
  • Exelixis Clinical Site #151
    Dresden, Saxony 01307, Germany
  • Exelixis Clinical Site #124
    Magdeburg, Saxony-Anhalt 39120, Germany
  • Exelixis Clinical Site #155
    Aachen, 52074, Germany
  • Exelixis Clinical Site #131
    Bonn, 53127, Germany
  • Exelixis Clinical Site #154
    Essen, 45147, Germany
  • Exelixis Clinical Site #160
    Freiburg im Breisgau, 79106, Germany
  • Exelixis Clinical Site #159
    Hamburg, 20246, Germany
  • Exelixis Clinical Site #139
    München, 81377, Germany
  • Exelixis Clinical Site #28
    Hong Kong, Hong Kong
  • Exelixis Clinical Site #46
    Budapest, 1122, Hungary
  • Exelixis Clinical Site #37
    Pécs, 7624, Hungary
  • Exelixis Clinical Site #43
    Haifa, 3109601, Israel
  • Exelixis Clinical Site #41
    Jerusalem, 9112001, Israel
  • Exelixis Clinical Site #58
    Petah Tikva, 4941492, Israel
  • Exelixis Clinical Site #109
    Viagrande, Catania 95029, Italy
  • Exelixis Clinical Site #135
    Catania, CT 95122, Italy
  • Exelixis Clinical Site #132
    Meldola, Forlì - Cesena 47017, Italy
  • Exelixis Clinical Site #144
    Genova, GE 16132, Italy
  • Exelixis Clinical Site #143
    Rozzano, Milano 20089, Italy
  • Exelixis Clinical Site #29
    Pisa, PI 56124, Italy
  • Exelixis Clinical Site #120
    Torino, TO 10126, Italy
  • Exelixis Clinical Site #103
    Milan, 20133, Italy

Showing the first 100 of 164 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Capdevila J, Krajewska J, Hernando J, Robinson B, Sherman SI, Jarzab B, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Williamson D, Levytskyy R, Oliver J, Keam B, Brose MS. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 2024 Mar;34(3):347-359. doi: 10.1089/thy.2023.0463. Epub 2024 Jan 23. PubMed 38062732 ↗
  • Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Hernando J, Faoro L, Banerjee K, Oliver JW, Keam B, Capdevila J. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 Aug;22(8):1126-1138. doi: 10.1016/S1470-2045(21)00332-6. Epub 2021 Jul 5. PubMed 34237250 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2018 to primary completion in Aug 2020, 22 months.

Results were first posted in May 2023, 2 years 8 months after primary completion. A results delay was requested in May 2021.

Completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Jul 2027, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2018
First posted
Oct 1, 2018
StartActual
Oct 5, 2018
Primary completionActual
Aug 19, 2020
CompletionEst.
Jul 31, 2027was Jul 2026
Results delay requested
May 5, 2021
Results first posted
May 18, 2023
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Jul 31, 2026→Jul 31, 2027
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Study completion Jul 31, 2026→Jul 31, 2027
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03690388
Lead sponsor
Exelixis
Collaborators
Ipsen
Responsible party
Sponsor
First posted
Oct 1, 2018
Start date
Oct 5, 2018
Primary completion
Aug 19, 2020
Completion
Jul 31, 2027 (estimated)
Results posted
May 18, 2023
Last update
Oct 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion